This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Characteristics

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Granulosa cell tumours are the most common, and account for 5% of all solid ovarian tumours. 5% occur before puberty, 40% after the menopause. 5% are bilateral. These tumours may be non-functional, oestrogenic or rarely, virilising. They may be associated with endometrial cancer in adults or or sexual pseudoprecosity in children. Histologically, they are characterised by Call-Exner bodies. Prognosis is generally good despite a tendency to recur.

Thecomas are one third as common as granulosa cell tumours. Two thirds occur after the menopause. They may secrete oestrogen or occasionally, be virilising. They are usually unilateral and benign. Often, tumours have both granulosa and thecal elements - granulosa-theca cell tumours.

Fibromas are solid benign tumours which consist entirely of fibrous tissue and do not secrete steroids. Frequently, they contain theca elements - fibrothecomas. They occur in Meig's syndrome.

Sertoli cell and Leydig cell tumours are rare. Mixed tumours may occur called arrhenoblastomas. They are usually androgenic.

Pure Leydig cell tumours are very rare, and may be referred to as lipid cell tumours. They are usually virilising producing adrenal corticoids and Cushing's syndrome. They are frequently located in the ovarian hilus.


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.